M&A Deal Summary |
|
|---|---|
| Date | 2015-11-27 |
| Target | Kremers Urban Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Lannett Company |
| Sellers(s) | UCB |
| Deal Type | Divestiture |
| Deal Value | 1.2B USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1942 |
| Sector | Medical Products |
| Employees | 810 |
| Revenue | 479M USD (2021) |
Lannett Company is a developer, manufacturer, packager, marketer and distributor of generic pharmaceutical products for a wide range of medical indications. Lannett Company was founded in 1942 and is based in Trevose, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2015 M&A | 2 of 2 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-06-02 |
Silarx Pharmaceuticals
Carmel, New York, United States Silarx Pharmaceuticals, Inc. is a manufacturer and marketer of high-quality liquid pharmaceutical products, including generic prescription and over-the-counter products. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1928 |
| Sector | Life Science |
| Employees | 9,000 |
| Revenue | 6.2B EUR (2024) |
UCB is a biopharma focused on severe diseases with operations in approximately 40 countries. UCB was incorporated in 1928 and is based in Brussels, Belgium.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 7 |
| Sector: Life Science M&A | 4 of 6 |
| Type: Divestiture M&A Deals | 3 of 6 |
| State: New Jersey M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-11-22 |
Lectus Therapeutics - Pharmaceutical Assets
United Kingdom Lectus Therapeutics - Pharmaceutical Assets engages in the discovery and development of Lectus' drug for the treatment of central nervous system. LEPTICS technology to identify compounds in a new area of chemical space. Such compounds are anticipated to possess a novel mechanism of action mediated through an effect on ion channel accessory proteins. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-02-01 |
UCB - Three Cardiovascular Products
Belgium UCB - Three Cardiovascular Products consists of Elantan®, Isoket® and Deponit® rights is a producer of medical products to treat both acute and chronic coronary artery disease. |
Sell | €92M |
